Zacks: Sientra, Inc. (SIEN) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Sientra, Inc. (NASDAQ:SIEN) have been assigned an average broker rating score of 2.00 (Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold recommendation and two have given a strong buy recommendation to the company. Sientra’s rating score has improved by 14.2% from three months ago as a result of various analysts’ upgrades and downgrades.
Analysts have set a 1 year consensus price objective of $12.67 for the company and are anticipating that the company will post ($0.63) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Sientra an industry rank of 187 out of 265 based on the ratings given to its competitors.
A number of research analysts have weighed in on SIEN shares. Zacks Investment Research downgraded Sientra from a “hold” rating to a “sell” rating in a report on Wednesday, May 17th. Lake Street Capital reiterated a “buy” rating and set a $15.00 target price (up previously from $11.00) on shares of Sientra in a report on Wednesday, August 2nd. Stephens started coverage on Sientra in a report on Tuesday, July 11th. They set an “overweight” rating and a $12.00 target price on the stock. ValuEngine upgraded Sientra from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, Canaccord Genuity started coverage on Sientra in a report on Monday. They set a “buy” rating and a $14.00 target price on the stock.
Sientra (SIEN) traded up 10.31% during trading on Monday, hitting $11.13. The stock had a trading volume of 359,106 shares. The company has a 50-day moving average of $10.63 and a 200 day moving average of $9.08. Sientra has a 52 week low of $6.92 and a 52 week high of $11.47. The company’s market cap is $214.88 million.
Sientra (NASDAQ:SIEN) last announced its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.04. Sientra had a negative return on equity of 52.30% and a negative net margin of 173.83%. The company had revenue of $8.20 million for the quarter, compared to the consensus estimate of $6.97 million. The business’s quarterly revenue was up 32.3% on a year-over-year basis. On average, equities research analysts anticipate that Sientra will post ($3.07) EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Cannell Capital LLC increased its position in Sientra by 2.3% in the first quarter. Cannell Capital LLC now owns 1,139,571 shares of the medical instruments supplier’s stock worth $9,595,000 after buying an additional 26,000 shares during the period. Segantii Capital Management Ltd increased its position in Sientra by 574.1% in the first quarter. Segantii Capital Management Ltd now owns 18,200 shares of the medical instruments supplier’s stock worth $153,000 after buying an additional 15,500 shares during the period. Blair William & Co. IL increased its position in Sientra by 2.0% in the first quarter. Blair William & Co. IL now owns 30,758 shares of the medical instruments supplier’s stock worth $299,000 after buying an additional 594 shares during the period. Wells Fargo & Company MN increased its position in Sientra by 0.3% in the first quarter. Wells Fargo & Company MN now owns 12,871 shares of the medical instruments supplier’s stock worth $108,000 after buying an additional 40 shares during the period. Finally, KCG Holdings Inc. purchased a new position in Sientra during the first quarter worth $147,000. Hedge funds and other institutional investors own 77.61% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/zacks-sientra-inc-sien-given-consensus-recommendation-of-buy-by-brokerages/1528438.html.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.